Table 2.
The most recently registered clinical trials for RSV vaccines, prophylactics and therapeutics since 2008
| Drug name | Clinical trial status | Manufacturer/Institution | Experimental approach | Outcome |
|---|---|---|---|---|
| Vaccines | ||||
| Live attenuated | ||||
| MEDI-559 | Phase 1/2a | MedImmune LLC | Live attenuated | Increased rate of LRTIs in vaccine recipients, further study ongoing |
| RSV LID ΔM2-2 | Phase 1 | NIAID | Recombinant live attenuated RSV | Estimated completion May 2016 |
| RSV cps2, Lot RSV#005A | Phase 1 | MedImmune, NIAID | Recombinant live Attenuated RSV | Estimated completion May 2015 |
| Chimeric/vectored | ||||
| RSV 001 | Phase 1 | Okairos | Adenovirus vector and an MVA vector encoding RSV antigens | Commenced May 2013 |
| Outcome awaited | ||||
| MEDI-534 | Phase I | MedImmune LLC | Chimeric/vectored | Genetic variants within vaccine detected. Ongoing research. |
| Nanoparticle | ||||
| RSV F nanoparticle vaccine | Phase 2 | Novavax | Recombinant RSV F protein particle | Commenced October 2013 Outcome awaited |
| Subunit | ||||
| MEDI 7510 | Phase 1a | MedImmune LLC | RSV sF antigen + synthetic glucopyranosyl lipid A adjuvant | Estimated completion July 2015 |
| RSV F subunit vaccine | Phase 1 | Novartis vaccines | F subunit vaccine | Estimated completion September 2016 |
| GSK3003891A | Phase 1 | GlaxoSmithKline (GSK) Biologicals | Prefusion F subunit vaccine | Estimated completion March 2015 |
| Prophylactics | ||||
| Motavizumab (Numax/MEDI-524) | Phase 3 (completed 2008) | MedImmune | Affinity-matured palivizumab | Increased type I hypersensitivity. |
| No FDA approval | ||||
| MEDI 557 | Phase 1 | MedImmune | Recombinant human monoclonal antibody | Completed May 2013. Data not available |
| MEDI 8897 | Phase 1b/2a | MedImmune | Human RSV monoclonal antibody | Estimated completion December 2014 |
| RI-001 | Phase 2 | ADMA biologics Inc | Polyclonal immune globulin. Delivered intravenously | Completed May 2010 |
| REGN2222 | Phase 3 | Regeneron pharmaceuticals | Human monoclonal anti-RSV F antibody | Estimated completion date February 2015 |
| Therapeutics | ||||
| GS-5806 | Phase 2b | Gilead | RSV entry inhibitor | Estimated completion June 2015 |
| ALN-RSV01 | Phase 2b (completed May 2012) | Ablynx | siRNA targeting the N protein | Reduced bronchiolitis obliterans post-RSV infection in lung transplant recipients. |
| ALS-008176 | Phase 2a | Alios biopharma Inc. | Nucleoside analogue | Estimated completion August 2014 |
| Danirixin | Phase 1 | GlaxoSmithKline | CXCR2 antagonist. | Estimated completion July 2014 |
| Inhibition of neutrophil activation | ||||
| RV568 | Phase 1 | Respivert Ltd | Kinase inhibitor | Completed 2011. Data not available |
| MDT-637 | Phase 1 | MicroDose Therapeutx, Inc | Fusion inhibitor | Commenced 2013. Data not available |
| ALX-0171 | Phase 1 | Ablynx | Nanobody | Commenced 2014 |
| Data not available | ||||